Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.69 |
| ▸ | CA12 | O43570 | 4/20 | 0.67 |
| ▸ | CA9 | Q16790 | 4/20 | 0.67 |
| ▸ | CA2 | P00918 | 3/20 | 0.67 |
| ▸ | CA7 | P43166 | 2/20 | 0.67 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.67 |
| ▸ | MEN1 | O00255 | 2/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.63 |
| ▸ | ATM | Q13315 | 2/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.56 |
| ▸ | THRB | P10828 | 1/20 | 0.56 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.56 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.56 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.56 |
| ▸ | CA1 | P00915 | 2/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | GLA | P06280 | 1/20 | 0.52 |
| ▸ | ANPEP | P15144 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20334978 | 1.00 | POLB (0.69) | POLBCA12CA9CA2CA7 | |
| SCHEMBL6435872 | 1.00 | POLB (0.69) | POLBCA12CA9CA2CA7 | |
| SCHEMBL6577060 | 0.88 | PPARG (0.60) | POLBCA12CA9CA2CA7 | |
| SCHEMBL27466542 | 0.88 | PPARG (0.60) | POLBCA12CA9CA2CA7 | |
| SCHEMBL20335114 | 0.88 | POLB (0.55) | POLBCA12CA9CA2CA7 | |
| SCHEMBL9819677 | 0.88 | POLB (0.55) | POLBCA12CA9CA2CA7 | |
| SCHEMBL28198277 | 0.87 | POLB (0.54) | POLBCA12CA9CA2CA7 | |
| SCHEMBL9082689 | 0.86 | CA12 (0.65) | POLBCA12CA9CA2CA7 | |
| SCHEMBL9082684 | 0.86 | CA12 (0.65) | POLBCA12CA9CA2CA7 | |
| SCHEMBL698061 | 0.85 | MMP2 (0.63) | POLBALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3342599-B1 | HEAT-SENSITIVE RECORDING MATERIAL | SANKO CO LTD (JP) | 2021-06-16 | — | — | EP | disclosed |
| US-10086634-B2 | Heat-sensitive recording material | SANKO CO., LTD. (JP) | 2018-10-02 | — | — | US | disclosed |
| US-20180194151-A1 | HEAT-SENSITIVE RECORDING MATERIAL | SANKO CO., LTD. (JP) | 2018-07-12 | — | — | US | disclosed |
| EP-3342599-A1 | HEAT-SENSITIVE RECORDING MATERIAL | Sanko Co., Ltd. (JP) | 2018-07-04 | — | — | EP | disclosed |
| EP-1505062-A1 | Heterocyclic derivatives and their use as antithrombotic agents | Akzo Nobel N.V. (NL) | 2005-02-09 | — | — | EP | disclosed |
| US-6797710-B2 | CARDIOVASCULAR DISORDERS; SERINE PROTEASE INHIBITOR; ADMINISTERING BY MOUTH; BIOAVAILABILITY | AKZO NOBEL N.V. (NL) | 2004-09-28 | — | — | US | disclosed |
| US-20030130270-A1 | Heterocyclic derivatives and their use as antithrombotic agents | MERCK SHARP & DOHME B.V. (NL) | 2003-07-10 | — | — | US | disclosed |
| US-6444672-B1 | ORAL BIOVAILABILITY; INHIBITORS OF THROMBIN AND/OR FACTOR XA; SERINE PROTEASE INHIBITOR | AKZO NOBEL N.V. (NL) | 2002-09-03 | — | — | US | disclosed |
| US-6432955-B1 | ANTICOAGULANTS | AKZO NOBEL N.V. (NL) | 2002-08-13 | — | — | US | disclosed |
| US-6194409-B1 | SERINE PROTEASE INHIBITOR; BIOAVAILABILITY WHEN ADMINISTERED BY MOUTH | AKZO NOBEL N.V. (NL) | 2001-02-27 | — | — | US | disclosed |
| EP-0975600-A1 | HETEROCYCLIC DERIVATIVES AND THEIR USE AS ANTITHROMBOTIC AGENTS | Akzo Nobel N.V. (NL) | 2000-02-02 | — | — | EP | disclosed |
| WO-1998047876-A1 | HETEROCYCLIC DERIVATIVES AND THEIR USE AS ANTITHROMBOTIC AGENTS | AKZO NOBEL N.V. (NL) | 1998-10-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180194151-A1 | HEAT-SENSITIVE RECORDING MATERIAL | ASIC1, SCN1A, NPR1 | POLB 3691/4885CA12 479/4885CA9 811/4885 |
| US-10086634-B2 | Heat-sensitive recording material | ASIC1, SCN1A, NPR1 | POLB 3884/4885CA12 469/4885CA9 655/4885 |
| US-20030130270-A1 | Heterocyclic derivatives and their use as antithrombotic agents | F2, F12, VKORC1 | POLB 3817/4885CA12 892/4885CA9 442/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.